Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| MBRX | 8-K | neutral | 4/10 | Moleculin Biotech held its 2026 Annual Meeting on October 9, 2026. Stockholders approved an amendment to the 2024 Stock | Oct 9, 2026 |
| QUCY | 424B5 | bearish | 7/10 | Quantum Cyber N.V. filed a 424B5 prospectus supplement for an at-the-market (ATM) equity offering of up to $100,000,000 | Oct 9, 2026 |
| SYRE | SC 13D/A | neutral | 3/10 | Fairmount Funds Management LLC filed Amendment No. 8 to its Schedule 13D on Spyre Therapeutics, reporting no change in b | Oct 9, 2026 |
| SXTC | 6-K | bearish | 7/10 | China SXT Pharmaceuticals (SXTC) filed a 6-K disclosing a securities purchase agreement for a registered direct offering | Oct 9, 2026 |
| PCVX | 8-K | bearish | 6/10 | Vaxcyte entered into a First Supplemental Indenture to issue $575M aggregate principal amount of 1.50% Convertible Senio | Oct 9, 2026 |
| GLASF | 6-K | neutral | 3/10 | Glass House Brands Inc. disclosed the planned retirement of CFO Mark Vendetti, effective March 31, 2027, with a successo | Oct 9, 2026 |
| VREOF | S-4 | neutral | 5/10 | Vireo Growth Inc. filed an S-4 registration statement for its acquisition of Planet 13 Holdings Inc. via a merger. Plane | Oct 9, 2026 |
| BIAF | 8-K | bearish | 6/10 | bioAffinity Technologies entered into a placement agency agreement and securities purchase agreement on October 8, 2026, | Oct 9, 2026 |
| HEPA | 8-K | mixed | 6/10 | Hepion Pharmaceuticals completed the acquisition of Gravitas Life Sciences (GLS), a clinical-stage biotech developing op | Oct 9, 2026 |
| QTTB | SC 13G | neutral | 4/10 | Frazier Life Sciences Public Fund, L.P. filed a new Schedule 13G disclosing a 5.9% passive stake in Q32 Bio Inc., holdin | Oct 9, 2026 |
| TCRT | 8-K | bearish | 7/10 | Alaunos Therapeutics received a delisting notice from Nasdaq on October 5, 2026, for failing to maintain the minimum $2. | Oct 9, 2026 |
| TENX | SC 13G/A | neutral | 3/10 | Dellora Investments LP filed an amended Schedule 13G disclosing a 6.4% passive stake in Tenax Therapeutics, up from a pr | Oct 9, 2026 |
| MYGN | 8-K | neutral | 3/10 | Myriad Genetics filed an 8-K reporting the separation of Chief Commercial Officer Brian Donnelly, effective September 21 | Oct 9, 2026 |
| PTCT | 144 | neutral | 2/10 | Mark Elliott Boulding, an officer of PTC Therapeutics, filed a Form 144 on October 9, 2026, indicating intent to sell 19 | Oct 9, 2026 |
| VRAX | 6-K | neutral | 3/10 | Virax Biolabs is restructuring its senior management, eliminating the COO role and appointing an Acting Chief Scientific | Oct 9, 2026 |
| CTTH | 8-K | neutral | 3/10 | CTT Pharmaceutical Holdings filed an 8-K with Item 4.01 (Change in Accountant), attaching a letter from predecessor audi | Oct 9, 2026 |
| CRVO | 8-K | neutral | 2/10 | CervoMed Inc. filed an 8-K under Item 7.01 to disclose that an investor presentation is available on its website. The fi | Oct 9, 2026 |
| DRMA | S-3 | neutral | 4/10 | Dermata Therapeutics filed an S-3 registration statement to register up to 6,919,560 shares of common stock for resale b | Oct 9, 2026 |
| ELTX | DEF 14A | neutral | 3/10 | Elicio Therapeutics filed its definitive proxy statement for the 2026 Annual Meeting of Stockholders to be held on Novem | Oct 9, 2026 |
| PCSA | S-3 | bearish | 7/10 | Processa Pharmaceuticals filed an S-3 registration statement to register up to 306,574,202 shares of common stock for re | Oct 9, 2026 |
| DERM | SC 13G/A | neutral | 4/10 | Wasatch Advisors LP filed an amended Schedule 13G disclosing a 11.0% passive stake in Journey Medical Corp as of Septemb | Oct 9, 2026 |
| TWST | 144 | neutral | 2/10 | Twist Bioscience officer Adam Laponis filed a Form 144 notice of intent to sell 2,462 shares of common stock, valued at | Oct 9, 2026 |
| PYXS | SC 13G/A | neutral | 4/10 | GordonMD Global Investments LP and affiliated entities filed an amended Schedule 13G on October 9, 2026, disclosing bene | Oct 9, 2026 |
| LNAI | 8-K | bearish | 6/10 | Lunai Bioworks submitted a formal request to Nasdaq on October 9, 2026, asking for an immediate trading suspension in it | Oct 9, 2026 |
| EXOZ | 8-K | neutral | 2/10 | EXOZYMES INC. filed an 8-K attaching an investor presentation dated October 6, 2026, that may be provided to investment | Oct 9, 2026 |
| BIAF | 424B5 | bearish | 7/10 | bioAffinity Technologies is raising approximately $4M in net proceeds through a registered direct offering of 116,545 co | Oct 9, 2026 |
| BIAF | 424B5 | neutral | 4/10 | bioAffinity Technologies filed a 424B5 prospectus supplement reducing the available shares under its ATM agreement with | Oct 9, 2026 |
| ZYME | 144 | neutral | 2/10 | Adam Schayowitz, an officer of Zymeworks Inc., filed a Form 144 on October 9, 2026, indicating intent to sell 13,832 sha | Oct 9, 2026 |
| SXTC | 424B5 | bearish | 7/10 | China SXT Pharmaceuticals is conducting a dilutive offering of up to 8,000,000 units (plus an over-allotment option for | Oct 9, 2026 |
| JAZZ | 8-K | neutral | 2/10 | Jazz Pharmaceuticals disclosed that EVP and Chief Commercial Officer Samantha Pearce plans to retire, effective upon app | Oct 9, 2026 |